Everyone who has fibromyalgia experiences it differently, which is one reason misunderstandings and myths often surround this ...

Tackling both the physical symptoms and emotional aspects can be key to improving the quality of life for those affected.

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 /This post was written and published as a collaboration between the in-house ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

Disturbed sleep is a prominent feature of fibromyalgia symptomatology and has been proposed as one of the core symptoms that should be systematically assessed in clinical trials for the treatment ...

TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

Some forms of exercise training and pharmacological-based interventions may improve fibromyalgia-related sleep disturbances, though evidence is limited.

Companies like Vertex on the acute pain side and Tonix targeting fibromyalgia on the chronic pain side, are aiming to be leaders in these burgeoning markets. With Tonix's treatment under FDA ...